Incidence of Adverse Cardiovascular Events in Patients Diagnosed with Cutaneous Leishmaniasis
DOI:
https://doi.org/10.55204/trc.v4i2.e359Keywords:
Glucantime, Leishmaniasis, Leishmaniasis cutáneaAbstract
Leishmaniasis is an endemic disease in Colombia affecting a large part of the national territory, associated with social, environmental, and climatological factors. It is caused by the parasite of the genus Leishmania, transmitted by the vector Lutzomyia. The disease has three clinical manifestations: cutaneous, mucocutaneous, and visceral. The first line of treatment for leishmaniasis is the medication Glucantime, dispensed upon confirmation of the disease through a direct lesion smear, where the parasite is evidenced under a microscope. Within the army, there are three health battalions dedicated to the verification, treatment, and follow-up of active organic patients of the institution, located in the cities of Bogotá, Medellín, and Bonza. The medication is administered intramuscularly or intralesionally, with doses of 10-20 mg/kg/day in 10-day cycles, being safe and effective. However, it has been noted that it is associated with adverse gastrointestinal, cardiovascular (arrhythmias), hepatic (transaminase alterations), and paraclinical alterations when used systemically. Therefore, monitoring treatment through paraclinical tests is of vital importance, especially in prolonged treatments and/or high doses.
This retrospective cohort study aims to determine the risk factors for cardiovascular adverse events in patients of the National Army who received treatment for Cutaneous Leishmaniasis with meglumine antimoniate, reported to SIVIGILA in the year 2018 in the city of Popayán.
Downloads
References
Patiño-Londoño, Sandra Yaneth, Salazar, Lina Marcela, Acero, Catalina Tovar, & Bernal, Iván Darío Vélez. (2017). Aspectos socio epidemiológicos y culturales de la leishmaniasis cutánea: concepciones, actitudes y prácticas en las poblaciones de Tierralta y Valencia, (Córdoba, Colombia). Salud colectiva, 13(Patiño, S; Sala-zar, Y; Tovar, C; Velez, I, 2017), 123-138. https://dx.doi.org/10.18294/sc.2017.1079 (Patiño, S; Salazar, Y; Tovar, C; Velez, I, 2017)
Leishmaniasis. Citado el octubre 3, 2022, de Paho.org página: https://www.paho.org/es/temas/leishmaniasis (Paho.org, 2022)
Fernández-Osorio, A. E., & Ramírez López, L. J. (2020). Editorial: Retos y perspectivas en seguridad multidi-mensional. Revista Científica General José María Córdova, 18(29), 1–2. doi:10.21830/19006586.569. (Fer-nández, A; Ramírez, L, 2020)
Ministerio de protección social, Instituto Nacional de Salud. Guía para la atención integral del paciente con Leishmaniasis. Organización Panamericana de la Salud OPS/OMS Convenio de Cooperación Técnica con el Ministerio de la Protección Social Nro. 256 de 2009 y Nro. 237 de 2010. Bogotá. 2010. (Organización Pan-americana de la Salud OPS/OMS, 2010)
García Bracamonte, B., Burillo Martínez, S., Morales Raya, C., & Ortiz Romero, P. (2022). S0001-7310(22)00539-7 10.1016/j.Ad.2022.06.011 García Bracamonte B hospital universitario 12 de octubre, Ma-drid, Spain. Electronic address: Beagarcia50@hotmail.com. Burillo Martínez S S hospital universitario 12 de octubre, Madrid, Spain. Morales Raya C C hospital universitario 12 de octubre, Madrid, Spain. Ortiz Romero P P hospital universitario 12 de octubre, Madrid, Spain. Eng spa case reports: electrocardiographic alterations re-lated to intralesional glucantime® treatments: A potentially severe adverse event. 2022 06 14. Actas Dermo-Sifiliograficas, 113(Grupo de Enfermedades Transmisibles Endoepidémicas y Relacionadas con Salud Sexual, 2022), T742–T744. doi:10.1016/j.ad.2022.06.011 (García, B; Burillo, S, et al, 2022)
Farina, J. M., García-Martínez, C. E., Saldarriaga, C., Pérez, G. E., Barbosa de Melo, M., Wyss, F. Baranchuk, A. (2021). Leishmaniasis y corazón. Archivos de cardiologia de Mexico, 92(Patiño, S; Salazar, Y; Tovar, C; Velez, I, 2017). doi:10.24875/acm.20000508 (Farina, J. M.; García-Martínez et al, 2021)
Protocolo de Vigilancia de Leishmaniasis. Grupo de Enfermedades Transmisibles Endoepidémicas y Relacio-nadas con Salud Sexual. Códigos 420-430-440 Versión: 05 Fecha: 28 marzo de 2022 (Grupo de Enfermedades Transmisibles Endoepidémicas y Relacionadas con Salud Sexual, 2022)
RUIZ, F; MOSCOSO, L. Et al. Lineamiento para la gestion y operación del programa de enfermedades trans-mitidas por vectores y zoonosis y otras consideraciones para la ejecución de sus transferencias nacionales de funcionamiento. Dirección de Promoción y Prevención Subdirección de Enfermedades Transmisibles Grupo Endemoepidémicas. 2020. (RUIZ, F; MOSCOSO, L. Et al, 2020)
Información para profesionales de la salud, pacientes y cuidadores. Dirección de medicamentos y grupos bio-lógicos grupo de farmacovigilancia. Ministerio de salud. INVIMA. 2016. (Ministerio de salud, 2016)
Maheshwari A, Seth A, Kaur S, Aneja S, Rath B, Basu S, et al. Toxicidad cardíaca acumulativa de estibogluco-nato de sodio y anfotericina B en el tratamiento de kala-azar. Pediatr Infect Dis J. 2011; 30 :180–1 (Ma-heshwari A; Seth A, 2011)
Farina, Juan Ma, García-Martínez, C. E., Saldarriaga, C., Pérez, G. E., Melo, M. B. de, Wyss, F., … Baranchuk, A. (2022). Leishmaniasis y corazón. Archivos de Cardiologia de Mexico, 92(1), 85–93. doi:10.24875/ACM.20000508
Dionísio, M. T., Dias, A., Rodrigues, F., Félix, M., & Estêvão, M. H. (2011). Paediatric visceral leishmaniasis: experience of a paediatric referral center 1990-2009. Acta medica portuguesa, 24(3), 399–404. Retrieved from https://pubmed.ncbi.nlm.nih.gov/22015026/
Shrivastava, R., Sinha, P. R., Singh, V. P., & Sundar, S. (2007). Echocardiographic evaluation of cardiac status in Indian visceral leishmaniasis patients. Transactions of the Royal Society of Tropical Medicine and Hygie-ne, 101(5), 429–432. doi:10.1016/j.trstmh.2006.08.005
Yazdi C, Narmani M. Visceral leishmaniasis with cardiac involvement in a three years old boy. Internet J In-fect Dis. 2003;2:1–4.
Rodríguez-González, M. J., Wadnipar-Gutiérrez, M. I., & Calvo-Betancourt, L. S. (2017). Miocarditis eosinofí-lica como causa de disfunción ventricular izquierda reversible. Revista colombiana de cardiología, 24(1), 56.e1-56.e5. doi:10.1016/j.rccar.2016.01.020
Mofredj A, Guerin JM, Leibinger F, Masmoudi R. Visceral leishmaniasis with pericarditis in an HIV-infected patient. Scand J Infect Dis. 2002;34:151–3.
Puerto-Alonso JL, Molina-Ruano FJ, Gómez-Soto F, Gómez-Rodríguez F. Visceral leishmaniasis with cardiac affectation in an immunocompetent patient. Med Clin (Barc) 2006;127:519.
Frapier JM, Abraham B, Dereure J, Albat B. Fatal visceral leishmaniasis in a heart transplant recipient. J Heart Lung Transplant. 2001;20:912–3.
Bemani E, Oryan A, Bahrami S. Effectiveness of amiodarone in treatment of cutaneous leishmaniasis caused by leishmania major. Exp Parasitol. 2019;205:107747.
Lawn SD, Armstrong M, Chilton D, Whitty CJ. Electrocardiographic and biochemical adverse effects of so-dium stibogluconate during treatment of cutaneous and mucosal leishmaniasis among returned travellers. Trans R Soc Trop Med Hyg. 2006;100:264–9.
Soares JR, Nunes MC, Leite AF, Falqueto EB, Lacerda BE, Ferrari TC. Reversible dilated cardiomyopathy associated with amphotericin B therapy. J Clin Pharm Ther. 2015;40:333–5.
Maheshwari A, Seth A, Kaur S, Aneja S, Rath B, Basu S, et al. Cumulative cardiac toxicity of sodium stiboglu-conate and amphotericin B in treatment of kala-azar. Pediatr Infect Dis J. 2011;30:180–1.
Lazcano-Ponce, E., Fernández, E., Salazar-Martínez, E., & Hernández-Avila, M. (2000). Estudios de cohorte. Metodología, sesgos y aplicación. Salud Pública de México, 42(3), 230–241.
Moreno-Altamirano, A., López-Moreno, S., & Corcho-Berdugo, A. (2000). Principales medidas en epidemio-logía. Salud Publica de Mexico, 42(4), 337–348. doi:10.1590/s0036-36342000000400009
Castro, M. Á., & Díaz, L. A. (2009). Las variables en el proceso de investigación en salud: importancia, clasifi-cación y forma de presentación en protocolos de investigación. MedUNAB, 12(3).
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Laura Andrea Muñoz Niño
This work is licensed under a Creative Commons Attribution 4.0 International License.
The authors retain the moral and patrimonial rights of their works. They only give to the magazine Tesla Revista Científica the right to the first publication of this. Since Tesla Revista Científica is an open access publication, readers can fully or partially reproduce its content as long as they properly credit the corresponding authors and the journal itself. Tesla Revista Científica undertakes not to make commercial use of the texts it receives and/or publishes.
Our journal is governed by the international policies SHERPA/RoMEO: Green journal: They allow the self-archiving of both the pre-print (draft of a paper) and the post-print (the version corrected and reviewed by peers) and even the final version ( layout as it will be published in the journal).
See also "Copyright and licences".
